Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Russell Katz

Showing results (1-10 of 20) with videos related to

Pageof 2
Sort By:
Epilepsia|August 16, 2003
Issues in clinical trial design from the FDA perspectiveRussell Katz
Epilepsy Research|December 27, 2005
FDA updateRussell Katz
CNS Spectrums|November 5, 2008
Food and Drug Administration regulationRussell Katz
Neurorx : the Journal of the American Society for Experimental Neurotherapeutics|February 18, 2005
Biomarkers and surrogate markers: an FDA perspectiveRussell Katz
Neurorx : the Journal of the American Society for Experimental Neurotherapeutics|February 18, 2005
FDA: evidentiary standards for drug development and approvalRussell Katz
The New England Journal of Medicine|July 19, 2013
Regulation of drugs for early Alzheimer's diseaseNicholas Kozauer, Russell Katz
The New England Journal of Medicine|March 15, 2013
Regulatory innovation and drug development for early-stage Alzheimer's diseaseNicholas Kozauer, Russell Katz
International Psychogeriatrics|September 30, 2005
Regulatory aspects of vascular dementia in the United StatesArmando Oliva, Ranjit Mani, Russell Katz
Movement Disorders : Official Journal of the Movement Disorder Society|December 6, 2017
New drugs for Parkinson's disease: The regulatory and clinical development pathways in the United StatesKarl Kieburtz, Russell Katz, C Warren Olanow
Movement Disorders : Official Journal of the Movement Disorder Society|October 7, 2020
A New Approach to the Development of Disease-Modifying Therapies for PD; Fighting Another PandemicKarl Kieburtz, Russell Katz, Andrew McGarry, et al.
Pageof 2

Showing results (1-10 of 20) with videos related to

Sort By:
Pageof 2
Epilepsia|August 16, 2003
Issues in clinical trial design from the FDA perspectiveRussell Katz
Epilepsy Research|December 27, 2005
FDA updateRussell Katz
CNS Spectrums|November 5, 2008
Food and Drug Administration regulationRussell Katz
Neurorx : the Journal of the American Society for Experimental Neurotherapeutics|February 18, 2005
Biomarkers and surrogate markers: an FDA perspectiveRussell Katz
Neurorx : the Journal of the American Society for Experimental Neurotherapeutics|February 18, 2005
FDA: evidentiary standards for drug development and approvalRussell Katz
The New England Journal of Medicine|July 19, 2013
Regulation of drugs for early Alzheimer's diseaseNicholas Kozauer, Russell Katz
The New England Journal of Medicine|March 15, 2013
Regulatory innovation and drug development for early-stage Alzheimer's diseaseNicholas Kozauer, Russell Katz
International Psychogeriatrics|September 30, 2005
Regulatory aspects of vascular dementia in the United StatesArmando Oliva, Ranjit Mani, Russell Katz
Movement Disorders : Official Journal of the Movement Disorder Society|December 6, 2017
New drugs for Parkinson's disease: The regulatory and clinical development pathways in the United StatesKarl Kieburtz, Russell Katz, C Warren Olanow
Movement Disorders : Official Journal of the Movement Disorder Society|October 7, 2020
A New Approach to the Development of Disease-Modifying Therapies for PD; Fighting Another PandemicKarl Kieburtz, Russell Katz, Andrew McGarry, et al.
Pageof 2